Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $299 from $289 and keeps an Overweight rating on the shares after meeting with management. Key discussion topics included lutikizumab in hidradenitis suppurativa, the company’s myriad drug combination development programs in inflammatory bowel disease, and AbbVie’s strategy regarding its TL1A-directed treatment in IBD and potentially in other settings.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch
- AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
- AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
- AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
- Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target